Clovis (CLVS): Solid Treatment Choice but Maintenance Use Seems Unlikely - Stifel
- Wall Street stocks fall as weak GDP growth spreads rate-cut gloom
- Q1 US GDP shows surprise slowing and uncomfortable inflation
- Alphabet (GOOGL) soars 16% on Q1 results beat, first-ever dividend
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil settles higher as weak U.S. economic growth offset by supply concerns
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Rubrik (RBRK) Prices Upsized 23.5M Share IPO at $32/sh
- After-hours movers: Alphabet, Microsoft, Snap, Intel, and more
- Midday movers: Meta, IBM, Caterpillar fall; Chipotle rises
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
Clovis Oncology Presents Efficacy and Safety Data from New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO Congress
October 7, 2016 8:45 AM EDTRucaparib NDA Dataset to be presented in oral presentation today at ESMO Rucaparib NDA currently under priority review with FDA Prescription Drug User Fee Act (PDUFA) date is February 23, 2017 European Marketing Authorization Application (MAA) submission planned for Q4 2016
BOULDER, Colo.--(BUSINESS WIRE)-- Clovis Oncology (NASDAQ: CLVS) announced today the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen.... More